Saturday 17 October 2026
Export IMNM’s income statement to Excel — free account
Immunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024. In the quarter to June 2026, revenue grew 69.8%, EPS fell 30.0% and free cash flow fell 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
16.47
0.93
−5.34%
Follow IMNM
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 4 |
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | — | 1.00 | (0.01) | 21.57 |
P/S ratio |
— | — | — | — | — | — | 15.59 | 68.88 | 149.04 |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (0.03) | (7.77) | 13.87 |
P/Operating CF |
— | — | — | — | — | — | (12.51) | (14.81) | (39.13) |
P/B ratio |
— | — | — | — | — | — | 1.82 | 3.44 | 2.96 |
Price to Tangible BV |
— | — | — | — | — | — | 1.82 | 3.44 | 2.96 |
EV/Sales |
— | — | — | — | — | — | 5.77 | 44.90 | 97.17 |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | (10.68) | (3.66) | (6.41) |
EV/FCF |
— | — | — | — | — | — | (9.62) | (3.44) | (6.10) |
Quick Ratio |
— | 1.03 | 1.53 | 13.09 | 5.06 | 2.77 | 6.33 | 4.00 | 14.53 |
Current Ratio |
— | 1.35 | 1.88 | 14.12 | 5.82 | 3.09 | 6.63 | 4.08 | 14.69 |
Net Debt/EBITDA |
— | 0.06 | 0.20 | 3.41 | 2.01 | 0.56 | 1.26 | 0.71 | 2.92 |
Debt/Assets |
0.00% | 26.44% | 11.15% | 1.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.51 | 0.17 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.05 | 0.02 |
Operating CF/Net income |
— | 0.94 | 0.92 | 0.68 | 0.74 | 0.76 | 0.07 | 0.38 | 0.90 |
Capex/Depreciation |
— | (0.44) | (0.38) | (0.78) | (0.10) | (0.39) | (3.85) | 9.00 | (83.49) |
Interest Coverage |
— | (75.91) | (107.79) | (322.66) | (2,520.40) | 7,380.20 | — | — | — |
| — | 25.79% | 34.34% | (624.22%) | (55.20%) | (115.73%) | (156.45%) | (194.63%) | (52.09%) | |
| — | (352.74%) | (219.69%) | (71.95%) | (48.24%) | (91.54%) | (123.77%) | (150.71%) | (46.00%) | |
ROIC |
— | (257.14%) | (503.31%) | (368.60%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (298.06%) | (330.82%) | (43.10%) | (51.73%) | (234.50%) | (85.48%) | (165.38%) | (33.69%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 164.71% | 1,432.83% | 2,554.19% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 140.23% | 364.51% | 630.57% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 44.39% | 174.18% | 370.12% |
Graham Net Nets |
— | — | — | — | — | — | 0.53 | 0.26 | 0.33 |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (48.96%) | (48.68%) | (11.27%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (3.84%) | (18.94%) | (10.69%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.71 | 0.15 | 0.08 |
Operating CF per Share |
— | (6.81) | (8.78) | (3.58) | (1.58) | (2.37) | (0.38) | (1.89) | (2.19) |
Capex per Share |
— | (0.21) | (0.21) | (0.17) | (0.01) | (0.02) | (0.04) | (0.12) | (0.11) |
Free Cash Flow per Share |
— | (7.02) | (8.99) | (3.75) | (1.59) | (2.39) | (0.42) | (2.01) | (2.30) |
Cash per Share |
— | 1.47 | 2.32 | 11.73 | 4.27 | 1.68 | 6.96 | 3.71 | 7.48 |
Shareholders Equity per Share |
— | 2.12 | 2.98 | 12.20 | 4.18 | 1.37 | 6.04 | 3.09 | 7.26 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 2.12 | 2.98 | 12.20 | 4.18 | 1.37 | 6.04 | 3.09 | 7.26 |
Free Cash Flow |
— | (7.63) | (9.83) | (12.72) | (18.30) | (28.94) | (8.40) | (117.97) | (200.60) |
Working Capital |
— | 0.55 | 1.46 | 39.86 | 46.91 | 15.32 | 122.87 | 167.03 | 615.79 |
Capital Expenditures |
— | (0.23) | (0.23) | (0.59) | (0.08) | (0.25) | (0.83) | (7.17) | (9.68) |
Net Current Asset Value |
— | (0.03) | 1.33 | 39.71 | 46.90 | 15.26 | 116.05 | 162.26 | 611.93 |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.79 | 1.40 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.25 | 0.36 | 0.49 | 0.88 | 0.93 | 0.10 | (0.08) | 0.01 |
Cash ROIC |
— | (150.10%) | (154.34%) | (15.59%) | (18.79%) | (78.26%) | (3.26%) | (29.61%) | (15.58%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | 2.61 | 2.61 | 2.58 | — | — | — |
Average Payables |
— | 0.51 | 0.51 | 0.87 | 2.13 | 2.74 | 2.86 | 8.75 | 8.76 |
Average Assets |
— | 2.22 | 4.75 | 24.79 | 51.23 | 40.99 | 86.29 | 194.39 | 461.71 |
Average Common Equity |
— | (30.42) | (30.42) | 2.86 | 44.77 | 32.42 | 68.27 | 150.52 | 407.75 |
Columns are period end dates